MARKET

AKTX

AKTX

Akari
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.840
+0.010
+0.55%
Opening 15:00 11/21 EST
OPEN
1.850
PREV CLOSE
1.830
HIGH
1.860
LOW
1.800
VOLUME
80.63K
TURNOVER
--
52 WEEK HIGH
9.20
52 WEEK LOW
1.560
MARKET CAP
29.08M
P/E (TTM)
-2.3590
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AKTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AKTX News

  • What Kind Of Shareholder Owns Most Akari Therapeutics, Plc (NASDAQ:AKTX) Stock?
  • Simply Wall St..3d ago
  • Akari Therapeutics Q3 2019 EPS $0.00 From $0.00 YoY
  • Benzinga.11/04 13:35
  • Akari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical Progress
  • GlobeNewswire.11/04 13:33
  • Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase I/II AKC Trial
  • GlobeNewswire.10/14 13:37

More

Industry

Biotechnology & Medical Research
-0.42%
Pharmaceuticals & Medical Research
+0.33%

Hot Stocks

Name
Price
%Change

About AKTX

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is conducting Phase Ib clinical trial of Coversin. It focuses on rare and orphan diseases, including disease states spanning hematology, nephrology, transplantation, neurology and ophthalmology.
More

Webull offers Akari Therapeutics PLC (ADR) (AKTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.